Navigation Links
New technique promises to 'lift the hood’ on autism
Date:5/18/2011

y, having inherited a deleterious mutation from a parent in addition to having a de novo mutation. The child with a FOXP1 mutation also inherited a defective copy of CNTNAP2, another gene that may be involved in language development. "It's like getting hit by lightning twice," Eichler says. That child has severe autism and the greatest language deficit of any individual in the study.

The child with the epilepsy-related SCN1A mutation also inherited from his mother a deletion that increases the risk for epilepsy; and indeed, that child has been diagnosed with epilepsy. The findings support the 'multi-hit' theory of autism, the idea that it may take a combination of mutations in the same pathway to cause severe autism or related disorders.

Studying 20 families is just a start "a teaser," as Eichler puts it. At the same time, the study offers two important proofs of principle: It provides compelling evidence that de novo point mutations may underlie many cases of autism, and it shows that exome-sequencing is an effective way to discover which of the more than 20,000 genes in the human genome are responsible for autism spectrum disorders.

"It's like having a dartboard with 20,000 candidates the fact that we could pick off four outstanding candidate genes is a great success," Eichler says. "It's proof on the ground that this technique is fruitful."

The Simons Foundation is providing funding for Eichler's team and several other groups to do whole-exome sequencing of several hundred families in the Simons Simplex Collection over the next few months. As whole-exome and eventually whole-genome sequencing become more accurate and affordable, it won't be long before it will be possible to sequence several thousand families, which should be enough data to provide statistical arguments about which genes are responsible for autism spectrum disorders, Eichler says.

"Within a couple of years, we should have a pretty comprehensive view
'/>"/>

Contact: Anastasia Greenebaum
agreenebaum@simonsfoundation.org
212-524-6097
Simons Foundation
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Molecular technique advances soybean rust resistance research
2. Penn researchers develop technique for measuring stressed molecules in cells
3. New technique improves sensitivity of PCR pathogen detection
4. Polarized microscopy technique shows new details of how proteins are arranged
5. Improvements in embryonic preimplantation genetic screening techniques
6. New technique tracks viral infections, aids development of antiviral drugs
7. Mapping the brain: New technique poised to untangle the complexity of the brain
8. DNA stretching -- A new technique being carried out at CIC microGUNE to detect illnesses
9. New imaging technique provides rapid, high-definition chemistry
10. New high-resolution carbon mapping techniques provide more accurate results
11. Combined molecular study techniques reveal more about DNA proteins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2015)... TRIANGLE PARK, North Carolina , 5. ... sein 35. Jahr als spezialisiertes Logistikunternehmen und ... Position als einzige klinische Logistikfirma (Clinical Logistics ... Die Kernbotschaft der neuen Kampagne lautet ... und Lieferungen. Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... SAN FRANCISCO , January 28, 2015 ... Camera Market Analysis, Size And Segment Forecasts To 2020 ... The global IR camera market is expected to reach ... study by Grand View Research, Inc. IR cameras help ... injuries, and are expected to witness surging demand in ...
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced ... Overview" report to their offering. , ... an individual is who she/he is claiming to be, and ... person,s unique physical characteristics, such as fingerprint, hand or palm ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
... so indelibly that their children are affected. History ... starvation, whose children experience altered physiology. Now ... University have found an instance of animals passing ... to their offspring. That information comes not through ...
... mapping how proteins interact with each other, developed at ... the design of new drugs for diseases such as ... acids, the Salk scientists determine the detailed molecular structure ... that turns it on. The switch--corticotrophin releasing factor type ...
... 29 November 2013 The American Association for the Advancement ... Science Policy Programme at EMBO, to its 2013 class of ... upon AAAS members by their peers and acknowledges contributions that ... been recognized by AAAS for her work looking at the ...
Cached Biology News:Mice can inherit learned sensitivity to a smell 2Mice can inherit learned sensitivity to a smell 3Salk scientists crack riddle of important drug target 2Salk scientists crack riddle of important drug target 3
(Date:2/27/2015)...  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology ... announced that it will be presenting at CALBIO 2015 ... nd at 3pm PST. Patrick Lucy, chief business officer ... current state of the biosimilar industry landscape entitled ... For more information on CALBIO 2015 and The ...
(Date:2/27/2015)... CA (PRWEB) February 27, 2015 Cytokinetics, ... forces on February 28 with patients and health care ... awareness for Rare Disease Day®. Rare Disease Day ... and calling attention to the special challenges faced by ... them. , “Cytokinetics is proud to stand alongside patients ...
(Date:2/27/2015)... , Feb. 27, 2015   PureTech , a ... and commercializing disruptive products and technologies in the healthcare ... , former CEO and Member of the Board of ... "It,s has been a pleasure to know ... that we will be working together more closely now," ...
(Date:2/26/2015)... 26, 2015 On behalf of biotech client ... Wilentz, Goldman & Spitzer, P.A. (Wilentz) secured a ... Genewiz Inc. in excess of $10 million. The jury ... secrets, and that it improperly hired one or more ... motions for judgment notwithstanding the verdict, a new trial, ...
Breaking Biology Technology:Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
... and VANCOUVER, Feb. 4 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ... survival rate from a Phase 1/2 clinical trial of ... of advanced non-small cell lung cancer (NSCLC). At two ... first-line chemotherapy were alive. OncoGenex has previously reported a ...
... introduction to the benefits of Shape Memory Alloys. The Kit is a ... a comprehensive manual, and easy to follow demonstrations on the morphing abilities ... ... -- Imagine a future where the only tool in an auto body ...
... HUNTINGTON BEACH, California and AMSTERDAM, February 4 ... diagnostics, today announced that,its signature breast cancer ... of,care for all eligible early stage breast ... Leeuwenhoek Hospital (NKI-AVL). The NKI-AVL,believes MammaPrint provides ...
Cached Biology Technology:OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer 2OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer 3OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer 4OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer 5Re-Shaping the Future with Shape Memory Alloys - SMA Starter Kit 2Re-Shaping the Future with Shape Memory Alloys - SMA Starter Kit 3Agendia's Breast Cancer Test MammaPrint(R) Standard of Care at Netherlands Cancer Institute - AVL 2
... The electrophoretic mobility shift assay (EMSA) ... interactions. Often referred to as gel shift ... on the principle that when subjected to ... a DNA-protein complex. The Pierce LightShift Chemiluminescent ...
... Lab Quantas unique combination of Coulter ... resolution capabilities and accurate cell counting. ... wavelengths, including UV, allowing flexible fluorochrome ... applications typically only achievable with larger, ...
... Genome-pULSe Kit delivers a novel procedure for ... labeling of whole genome DNA from small ... provide a quick and highly reproducible amplification ... consists of a REPLI-g Mini Kit module ...
... using PULSin may be superior to transfection ... traditional transfection, with PULSin you can study ... time course of proteins in cells. Likewise, ... information than traditional RNA interference experiments. ...
Biology Products: